Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...
The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric ...
The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...
Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...